US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Faron 2024 Half-Year Financial Results

Faron Pharmaceuticals Ltd. (“Faron” or “the Company”)   Faron Reports Half-Year Financial Results, 1 January – 30 June 2024     Company Announcement, 27 August 2024   Summary Highlights     · Initial preliminary phase II data read-out from the BEXMAB trial confirmed earlier positive phase I findings in myelodysplastic syndrome (MDS) patients that have failed with hypomethylating agent (HMA), reinforcing bexmarilimab’s potential to improve the therapeutic benefit for patients with aggressive hematological malignancies who do not respond to the current standard

FDA Grants Fast Track Designation for Bexmarilimab

Faron Pharmaceuticals Ltd.   (“Faron” or the “Company”)     Inside Information: FDA Grants Fast Track Designation for Bexmarilimab in r/r MDS   Company announcement, Inside Information, 26 August 2024 at 7:00 a.m. BST / 9:00 a.m. EEST   Key highlights -          Given the strong data seen in Phase 1 and continuing in Phase 2 of Faron’s BEXMAB trial, the FDA has granted Fast Track Designation (FTD) for bexmarilimab for the treatment of r/r MDS -          FTD further strengthens the bexmarilimab program by offering clinical development and commercialization

Update to Faron’s Financial Calendar for 2024

Faron Pharmaceuticals Oy(“Faron” or “Company”)   Update to Faron’s Financial Calendar for 2024     Company announcement February 27, 2024 at 1:00 p.m. EST / 6:00 p.m. GMT / 8:00 p.m. EET TURKU, FINLAND / BOSTON, MA – February 27, 2024 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on tackling difficult-to-treat cancers and inflammation via precision immunotherapy, today announces an update to its financial reporting calendar for 2023, further to the to the announcement on December 22, 2023.   The

Faron to Present at the H.C. Wainwright BioConnect Virtual Conference

Faron Pharmaceuticals Ltd (“Faron”)   Faron to Present at the H.C. Wainwright BioConnect Virtual Conference   Press Release, January 5, 2022 at 02:00 AM (EDT) / 07:00 AM (GMT) / 09:00 AM (EET)   TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron, will present at the H.C. Wainwright

Faron Appoints Marie-Louise Fjällskog as CMO

Company announcement, January 3, 2022 at 02:00 AM (EST) / 07:00 AM (GMT) / 09:00 AM (EET)TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, is pleased to announce the appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer of the Company. Dr. Fjällskog will be based in Boston, MA and her appointment is effective immediately.   Dr. Fjällskog has over 30 years of

Faron Announces Topline MATINS Biomarker Analysis

Faron Pharmaceuticals Ltd. (“Faron”) Topline Biomarker Analysis Shows Bexmarilimab Ignites Immune Response in Patient Population That Has Not Traditionally Benefited from Current Immunotherapy Treatments · Patients with low baseline levels of inflammatory cytokines in blood achieved significantly higher clinical benefit following treatment with bexmarilimab monotherapy · Low inflammatory biomarker profile is likely to predict bexmarilimab monotherapy clinical benefit   · Ignition of immune response, as indicated by increased levels of inflammatory cytokines following

Presentation of Updated MATINS Data at ESMO

Faron Pharmaceuticals Ltd. (“Faron”) Faron Announces Presentation of Updated MATINS Data at ESMO Showing Bexmarilimab Delivers Compelling Antitumour Activity Across Five Different Advanced Solid Tumors   ·Strongest disease control rate (DCR) observed in five different tumor types – cutaneous melanoma (30%), gastric cancer (30%), cholangiocarcinoma (30%), hepatocellular carcinoma (40%) and breast cancer (40%) patients · Landmark analysis estimates overall survival at six months for DCR (partial response + stable disease rate) patients at 83% compared to 29% for non-DCR

First Patient Dosed in Phase II/III COVID-19 Trial

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron Pharmaceuticals Doses First Patient in Phase II/III HIBISCUS Trial of Traumakine for Treatment of Hospitalized COVID-19 Patients ·Trial co-funded by US Department of Defense Company announcement, August 25, 2021 at 9.00 AM (EEST)Inside information TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today

Updated corporate presentation

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Updated corporate presentation Company announcement, 22 June 2021 at 9.00 AM (EEST)  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, has today published an updated corporate presentation on its website. The presentation contains previously published Company information, views of Management and data from Faron’s development programmes. Latest available data from the ongoing PhI/II MATINS trial investigating bexmarilimab, Faron's wholly-owned novel

Bexmarilimab granted key US patent

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Bexmarilimab granted key US patent  Company announcement, 14 June 2021 at 9.00 AM (EEST)  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the United States Patent and Trademark Office has granted a new US Patent, No. 11,046,761, with claims protecting the composition of matter of bexmarilimab. The patent will be issued on 29 June, 2021. Faron's wholly-owned novel precision cancer immunotherapy drug candidate, bexmarilimab,

Bexmarilimab results published in CCR

Faron Pharmaceuticals Oy (“Faron” or the “Company”) First-in-human bexmarilimab results published in Clinical Cancer Research - Results reveal the role of Clever-1 receptor in supressing adaptive immunity - Bexmarilimab’s macrophage-targeting approach activates T-cells and drives anti-tumour immune responses in cold tumours that are not otherwise responsive to immunotherapy Company announcement, 3 June 2021 at 9.00 AM (EET)  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces the

Bexmarilimab shows promising anti-tumour activity

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Bexmarilimab monotherapy shows promising anti-tumour activity in multiple advanced solid tumours · Headline data reported from patients enrolled in completed Part I and ongoing Part II of MATINS study · Strongest disease control rate (DCR) of 31% seen in cutaneous melanoma, gastric cancer and cholangiocarcinoma patients · 100% six-month survival rate observed in DCR patients compared with 31.1 % for non-DCR patients · Equivalent prior treatment durations for DCR and non-DCR patients suggests DCR with bexmarilimab is

US rights to patent related to Traumakine

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron secures U.S. rights to patent related to Traumakine  Company announcement, 14 May 2021 at 9.00 AM (EEST)  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that it has signed a sub-license agreement for the rights to U.S. patent US9,376,478, which currently extends to 2033. The agreement clarifies Faron’s intellectual property position in the U.S. ahead of any launch of Traumakine for the treatment of capillary leak and systemic

Faron´s Annual Report 2020 published

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron´s Annual Report 2020 published Company announcement, 25 March 2021 at 9.15 AM (EET)  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that its Annual Report for the year 2020 has been published today. Faron Pharmaceuticals´ Annual Report 2020 and audited financial statements for the accounting period 1 January - 31 December 2020 have been published in English and its financial statements in Finnish, on the Company's website https://www.

Financial statement January 1 to December 31 2020

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Financial statement release January 1 to December 31, 2020   ·Clevegen[®] (bexmarilimab) Phase I/II MATINS study has shown early clinical benefits in six hard-to-treat solid cancers with further combination studies planned · Intravenous interferon beta-1a Traumakine[®], for organ damage protection, now also investigated as potential COVID-19 treatment · Company’s balance sheet strengthened by successful share placings of €14 million and €15 million (post period) · Additional grants of €3.3 million and €4.6 million

Notice of Full-Year Results and Annual Report

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Notice of Full-Year Results and Annual Report Company announcement, 25 February 2021 at 7.00 am GMT / 9.00 am EET TURKU, FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company, will publish its audited full-year results for the twelve months ended 31 December 2020 on Thursday 25 March 2021 at 7:00 GMT / 9:00 EET. The Annual Report 2020, including audited financial statements for the full year, will be published on the same day. A virtual briefing and Q&A session for

Update on TRAUMAKINE development

Faron Pharmaceuticals Oy (“Faron” or the “Company”) · U.S. Food and Drug Administration (FDA) approval of new HIBISCUS study protocol in patients with COVID-19 infection · Company seeking patent protection for the sequential use of IV interferon beta-1a and corticosteroids · Pipeline expansion into additional organ protection indications · CMC scale-up in progress Company announcement, 26 January 2021 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces

Presentations at ESMO Immuno-Oncology Virtual Congress build case for CLEVER-1 as a new immune checkpoint target

Data from ongoing PhI/II MATINS trial showcasedRole of myeloid cells in shaping the tumour microenvironment highlightedCompany announcement, 10 December 2020 at 9.00 AM (EET)TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that two presentations at the European Society of Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 will showcase data from the Company’s PhI/II MATINS study and explore the role of myeloid cells in shaping the tumour microenvironment (TME). ‘CLEVER-1 a new immune

Bexmarilimab (Clevegen) development update

· Accumulating MATINS data build foundation for further clinical development · Five patient cohorts in MATINS study Part II already fully recruited · Higher frequency of dosing introduced to investigate potential for enhanced clinical responses · Three new trials will study bexmarilimab treatment in neoadjuvant setting, in combination with PD(L)-1 checkpoint inhibitor and in haematological malignanciesCompany announcement, 23 November 2020 at 9.00 AM (EET)  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company,

Notice of Half-Year Report

Faron Pharmaceuticals Ltd (“Faron” or the “Company”)Company announcement, 27 August 2020 at 9.00 AM (EET) TURKU – FINLAND, 27 August 2020 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, will announce its unaudited half-year report for the six months ended 30 June 2020 on Thursday 24 September 2020. Dr. Markku Jalkanen, Chief Executive Officer, Toni Hänninen, Chief Financial Officer, and Yrjö Wichmann, VP Financing will host a conference call and webcast followed by a Q&A session at 12:30 pm BST (7:30 am EST) to discuss the financial

Change of Adviser

Faron Pharmaceuticals Oy (“Faron” or the “Company”)Company announcement, 27 July 2020 at 9.00 AM (EET) TURKU - FINLAND, 27 July 2020 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, is pleased to announce that Cairn Financial Advisers LLP has been appointed as Nominated Adviser to the Company with immediate effect.  Panmure Gordon (UK) Limited continues to act as the Company’s Broker. For further information, please contact: Faron Pharmaceuticals Oy Dr Markku Jalkanen, Chief Executive Officer investor.relations@faron.

Managers’ transactions

(“Faron” or the “Company”)Company announcement, 8 July 2020 at 5 PM (EEST) TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that Mr Toni Hänninen, Chief Financial Officer of the Company, acquired 4,400 ordinary shares in Faron at a price of €3.510 per share on 8 July 2020. Following these purchases, Mr Hänninen holds 54,697 ordinary shares in the Company. The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe